MT-125
Glioblastoma (GBM), MGMT unmethylated
Phase 1/2Active
Key Facts
About Myosin Therapeutics
Myosin Therapeutics is an early-stage, private biotech company developing a novel class of therapeutics that target molecular motors, a largely unexplored mechanism in drug discovery. The company's platform focuses on disrupting the cellular mechanics of cancer progression and dysregulated brain plasticity, moving beyond traditional signaling pathway inhibition. With a lead Phase 1/2 trial for glioblastoma set to begin in 2026 and a seasoned leadership team with deep drug development expertise, Myosin is positioning itself to tackle high-unmet-need conditions in oncology and neuroscience. The company is currently pre-revenue and in the pre-clinical to early clinical stage of development.
View full company profile